Pancreatic Cancer Research

ResearcherGeorge Washington UniversityActive in the last 2 years

George Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3283-1194; OpenAlex author ID A5038092134. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.36469/001c.124367↗
  2. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/03007995.2022.2059976↗
  3. Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies. Last author PMID 34267862↗
  4. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  5. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. Last author DOI 10.1177/1758835920944052↗
  6. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Co-author DOI 10.1177/1758835919850367↗
  7. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. Co-author DOI 10.1186/s12885-017-3131-x↗
  8. nab-Paclitaxel for the treatment of pancreatic cancer. Co-author DOI 10.2147/cmar.s127840↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul C. Cockrum · 4 shared papers, 2020–2024 · strength 0.78
  2. Gabriela Dieguez · 2 shared papers, 2021–2024 · strength 0.45
  3. Prachi Bhatt · 1 shared paper, 2024 · strength 0.28
  4. Zev A. Wainberg · 1 shared paper, 2022 · strength 0.20
  5. Samantha Tomicki · 1 shared paper, 2021 · strength 0.17
  6. Jim M. Koeller · 1 shared paper, 2020 · strength 0.13
  7. Salah Eddin Al-Batran · 1 shared paper, 2019 · strength 0.12
  8. Winson Y. Cheung · 1 shared paper, 2019 · strength 0.12
  9. Guido Giordano · 1 shared paper, 2019 · strength 0.12
  10. Elena Gabriela Chiorean · 1 shared paper, 2019 · strength 0.12
  11. Mitesh J. Borad · 1 shared paper, 2020 · strength 0.09
  12. Thomas C. Smyrk · 1 shared paper, 2020 · strength 0.09
  13. Angela L. McCleary‐Wheeler · 1 shared paper, 2020 · strength 0.09
  14. Alex A. Adjei · 1 shared paper, 2020 · strength 0.09
  15. Rondell Patrell Graham · 1 shared paper, 2020 · strength 0.09
  16. Ryan Michael Carr · 1 shared paper, 2020 · strength 0.09
  17. Charles Erlichman · 1 shared paper, 2020 · strength 0.09
  18. Tanios Bekaii‐Saab · 1 shared paper, 2020 · strength 0.09
  19. Martín E. Fernández-Zapico · 1 shared paper, 2020 · strength 0.09
  20. Dick J. Richel · 1 shared paper, 2017 · strength 0.05
  21. Donald Richards · 1 shared paper, 2017 · strength 0.05
  22. Berta Laquente · 1 shared paper, 2017 · strength 0.05
  23. Emiliano Calvo Aller · 1 shared paper, 2017 · strength 0.05
  24. Tudor–Eliade Ciuleanu · 1 shared paper, 2017 · strength 0.05
  25. Stefano Cascinu · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.